Updated March 26 at 6:25pm
health care

Calmar Pain Relief opens new facility


WEST WARWICK – Calmar Pain Relief LLC, a firm employing noninvasive technology known as Scrambler Therapy to treat severe chronic, high-intensity pain, opened its new, expanded, 4,000 square-foot treatment center on Jan. 3.

Scrambler Therapy uses a computerized medical device that transmits synthetic nonpain information through disposable surface electrodes on the skin (similar to an EKG) to surface nerve receptors, according to company officials. Artificial neurons transmit synthetic nonpain information to the central nervous system, in turn substituting endogenous pain information with synthetic nonpain information, which the central nervous system recognizes as “self” and “non-pain.”

Calmar uses this U.S. FDA 510 (k) cleared technology to offer a rapid, noninvasive, non-narcotic and painless treatment for various types of chronic neuropathic and oncologic pain, according to Dr. Stephen D’Amato, the firm’s medical director.

Since opening its first facility in North Providence, the first of its kind in the United States, Calmar has treated more than 270 patients with various types of chronic neuropathic and oncologic pain, with a success rate of more than 80 percent, according to company officials. The new West Warwick treatment center will centralize Calmar’s operations, more than doubling its capacity to treat patients as well as providing state-of-the-art research facilities for the further development of the technology.

Because this process is biophysical rather than chemical, all risks of harmful side effects are erased, according to company officials. In a typical 10-session treatment cycle of Scrambler Therapy, pain is progressively reduced in intensity until complete resolution. The pain relief is long term (three months to one year), although the Scrambler Therapy can be repeated as needed, company officials added. No adverse side effects have been recorded with the Scrambler Therapy.


No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News